Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Px-102. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 known ✓ | Q96RI1 | 20/20 | 1.00 |
| ▸ | FXR2 | P51116 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Px-102 SCHEMBL1164533 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL29366746 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL29823470 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL17087855 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL17087854 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL19633868 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL24662891 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL17087850 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL17087856 | 1.00 | NR1H4 (1.00) | NR1H4FXR2 | |
| Px-102 SCHEMBL12098287 | 0.95 | NR1H4 (0.91) | NR1H4FXR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4090327-B1 | USE OF FXR AGONISTS FOR TREATING AN INFECTION BY HEPATITIS D VIRUS | INST NAT SANTE RECH MED (FR) | 2025-03-05 | — | — | EP | disclosed |
| US-20240216364-A1 | STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT | ENYO PHARMA (FR) | 2024-07-04 | — | — | US | disclosed |
| US-20240100125-A1 | SYNERGISTIC EFFECT OF A FXR AGONIST AND IFN FOR THE TREATMENT OF HBV INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-03-28 | — | — | US | disclosed |
| US-20230060715-A1 | USE OF FXR AGONISTS FOR TREATING AN INFECTION BY HEPATITIS D VIRUS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-03-02 | — | — | US | disclosed |
| US-20220241376-A1 | METHOD FOR DECREASING ADVERSE-EFFECTS OF INTERFERON | ENYO PHARMA (FR) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241376-A1 | METHOD FOR DECREASING ADVERSE-EFFECTS OF INTERFERON | IFNG, IFNAR1, IRF3 | NR1H4 1756/4885FXR2 1267/4885 |
| US-20240100125-A1 | SYNERGISTIC EFFECT OF A FXR AGONIST AND IFN FOR THE TREATMENT OF HBV INFECTION | NR1H4, IFNG, IFNAR1 | NR1H4 1/4885FXR2 6/4885 |
| US-20240216364-A1 | STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT | TLR3, NR1H4, TLR9 | NR1H4 2/4885FXR2 4/4885 |
| US-20230060715-A1 | USE OF FXR AGONISTS FOR TREATING AN INFECTION BY HEPATITIS D VIRUS | NR1H4, FXR1, FXR2 | NR1H4 1/4885FXR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.